JunHe Assists La Chapelle in Obtaining Court Approval for its Reorganization Plan after its A+H-Share Delisting and the Granting of a Whitewash Waiver by the SFC
On May 16, 2025, the reorganization plan of Xinjiang La Chapelle Fashion Co., Ltd. (‘La Chapelle’) was approved by the Shanghai Third Intermediate People’s Court (‘Shanghai Third Intermediate Court’). JunHe acted as the administrator, and partner Li Chenghao led JunHe’s team and acted as the principal. La Chapelle was established on March 14, 2001, and …
JunHe Assists Meituan in Its Largest Overseas Senior Bond Issuance
In November 2025, Meituan successfully completed a dual-currency bond issuance in US dollars and offshore RMB notes. The total issuance was USD 3 billion, including USD 600 million in 5.5-year bonds, USD 600 million in 7-year bonds, USD 800 million in 10-year bonds, RMB 2.08 billion in 5-year bonds and RMB 5 billion in 10-year …
Continue reading “JunHe Assists Meituan in Its Largest Overseas Senior Bond Issuance”
JunHe Assists Simcere Zaiming in a Strategic Partnership with NextCure Worth Over USD 700 million
On June 16, 2025, Simcere Zaiming, an innovative oncology-focused subsidiary of Simcere Pharmaceutical Group (HKEX: 2096), announced a strategic partnership with the U.S. biopharmaceutical company NextCure, Inc. (Nasdaq: NXTC). The partnership aims to jointly develop a novel antibody-drug conjugate (ADC) targeting CDH6, named SIM0505. The collaboration includes licensing NextCure to use Simcere Zaiming’s proprietary linker …
JunHe Assists TOP TOY in its Strategic Financing
JunHe recently served as the legal counsel to TOP TOY International Group Limited (TOP TOY) and assisted it in completing a strategic financing round led by Temasek. The post-money valuation of this financing stands at approximately HKD 10 billion, showcasing the market recognition of TOP TOY’s business model, brand equity and global expansion roadmap amidst …
Continue reading “JunHe Assists TOP TOY in its Strategic Financing”
Bär & Karrer advised Tecan on the issuance of CHF 150 Million bonds
On 14 August 2025 Tecan Group Ltd. (SIX Swiss Exchange: TECN) successfully issued CHF 150 million 0.85% fixed rate domestic straight bonds due 2030. The bonds are listed and traded on the SIX Swiss Exchange. UBS Investment Bank and Zürcher Kantonalbank acted as joint lead managers, with Bank J. Safra Sarasin serving as co-lead manager.
Hogan Lovells berät PATRIZIA beim Erwerb einer Seniorenresidenz von Cureus
11. Dezember 2025 – Unter der Leitung der Hamburger Counsel Claudia Wolf hat die globale Wirtschaftskanzlei Hogan Lovells den internationalen Investmentmanager für Immobilien und Infrastruktur PATRIZIA beim Erwerb einer Seniorenresidenz im Rahmen eines Asset Deals von Cureus, einem auf stationäre Pflegeimmobilien spezialisierten Entwickler und Bestandshalter, beraten.
Gernandt & Danielsson advises ADDvise in connection with a public offer from Amplex
On 10 December 2025, Amplex AB announced a public cash offer to the shareholders of ADDvise Group AB (publ). The offer values all shares and warrants in ADDvise at SEK 1.05 billion. The board of directors of ADDvise will evaluate the offer and announce a statement with its opinion regarding the offer and a fairness …
Bär & Karrer Advises L’Oréal on the increase of its stake in Galderma from 10% to 20%
L’Oréal, the world leader in beauty, acquires an additional 10% stake in Galderma Group AG (Galderma), the pure-play dermatology category leader and one of the world’s largest players in injectable aesthetics, from Sunshine SwissCo AG, Abu Dhabi Investment Authority, and Auba Investment Pte. Ltd. (a consortium led by EQT).
Chambers & Partners recognises Arbor Law for its distinctive “Big Law without the baggage” model.
Arbor Law has been recognised in the Chambers UK 2025 Guide for its outstanding work supporting small and medium-sized enterprises (SMEs) across the UK – a testament to the firm’s innovative, senior-only model that combines City-firm expertise with in-house commercial insight, designed to eliminate inefficiency and make excellence more accessible to small and mid-sized businesses seeking legal support.
Regulation of Clinical Trials in the Republic of Kazakhstan
What is a clinical trial? A clinical trial (“CT”) is a study involving human subjects, conducted to identify or confirm the safety and effectiveness of means, methods, and technologies for the prevention, diagnosis, and treatment of diseases. What types of CTs are there? A non-interventional CT is a study which is conducted after the state …
Continue reading “Regulation of Clinical Trials in the Republic of Kazakhstan”